Experimental biologic aims to eliminate persistent HPV16 infection
NCT ID NCT07710703
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests whether an experimental biologic called NWRD09 can clear persistent cervical HPV16 infection in women aged 45 to 65. Participants receive either NWRD09 or a placebo by injection, and researchers check if the virus is gone after 16 weeks. The trial also monitors for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental biologic called NWRD09
- What this could lead to
- If successful, this could offer a way to clear persistent HPV16 infection, potentially reducing the risk of cervical cancer.
- What could go wrong
- This is an early-stage trial with only 60 participants, so results may not apply broadly. The treatment may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT CERVICAL HPV16 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, China